EichorEICHOR
Study identifier: NCT05858619 Synced from ClinicalTrials.gov · August 02, 2026
● Recruiting

Molecular Signatures of Cutaneous Dupilumab Response

Condition: Atopic Dermatitis  ·  Sponsor: University of California, San Francisco

PhasePhase 4
Planned participants15
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

This description comes directly from the study's public registry record.

Talk to the study team

Jeffrey Cheng, MD, PhD  ·  415 575 0524  ·  rashes@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05858619